MYndspan, a London-based neurotechnology company offering clinical-grade MEG brain scans to consumers, has secured a strategic investment from EMOTIV, a global leader in wearable EEG and mental performance tracking. The funding forms part of MYndspan’s ongoing crowdfunding campaign, which launched today.
The partnership combines MYndspan’s MEG-based brain health assessments with EMOTIV’s real-time EEG technology, aiming to bridge the gap between advanced clinical insights and everyday brain tracking. The collaboration is intended to make proactive brain health monitoring more accessible and personalised.
Founded to bring hospital-grade neuroscience into the hands of consumers, MYndspan’s platform provides metrics such as Functional Brain Age and the Brain Stability Index — indicators designed to detect early signs of cognitive decline, neurodegeneration and injury, years before symptoms arise.
EMOTIV’s consumer devices, including the Emotiv App and MN8 earbuds, are already used to deliver real-time insights on cognitive states like focus, stress and mental fitness. Through integration with MYndspan’s MEG-derived biomarkers, the combined platform will offer deeper, longitudinal insights into individual brain health.
The investment builds on MYndspan’s recent partnerships with BIOS Health, MEGIN, IMEDCO and Re:Cognition Health, as the company continues its mission to bring clinical-grade brain scanning to a broader, consumer-focused market. The company’s first flagship site in London is set to open later this year.
